173 related articles for article (PubMed ID: 32058070)
1. Vedolizumab therapy in common variable immune deficiency associated enteropathy: A case series.
Sifers T; Hirten R; Mehandru S; Ko HM; Colombel JF; Cunningham-Rundles C
Clin Immunol; 2020 Mar; 212():108362. PubMed ID: 32058070
[TBL] [Abstract][Full Text] [Related]
2. Vedolizumab Induced Clinical, Endoscopic, and Histological Improvement in Common Variable Immunodeficiency Disease-associated Intestinal Enteropathy.
Akhtar HJ; Markandey B; Ma C; Ramsewak D; Walsh JC; Jairath V
Inflamm Bowel Dis; 2020 Mar; 26(4):e22-e23. PubMed ID: 32002555
[No Abstract] [Full Text] [Related]
3. Vedolizumab in Patients With Common Variable Immune Deficiency and Gut Inflammation.
Boland BS; Riedl MA; Valasek MA; Crowe SE; Sandborn WJ
Am J Gastroenterol; 2017 Oct; 112(10):1621. PubMed ID: 28978958
[No Abstract] [Full Text] [Related]
4. CVID enteropathy is characterized by exceeding low mucosal IgA levels and interferon-driven inflammation possibly related to the presence of a pathobiont.
Shulzhenko N; Dong X; Vyshenska D; Greer RL; Gurung M; Vasquez-Perez S; Peremyslova E; Sosnovtsev S; Quezado M; Yao M; Montgomery-Recht K; Strober W; Fuss IJ; Morgun A
Clin Immunol; 2018 Dec; 197():139-153. PubMed ID: 30240602
[TBL] [Abstract][Full Text] [Related]
5. Infliximab as treatment of severe enteropathy in a patient with common variable immunodeficiency and cytomegalovirus infection.
Prieto Elordui J; Arreba Gonzalez P; Ortiz de Zarate Sagastagoitia J; Deiss Pascual L; Blanco Sampascual S; Baranda Martín A; Calderón García A; Muñoz Villafranca C
Gastroenterol Hepatol; 2018 Mar; 41(3):163-164. PubMed ID: 28476306
[No Abstract] [Full Text] [Related]
6. Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype.
Lord JD; Long SA; Shows DM; Thorpe J; Schwedhelm K; Chen J; Kita M; Buckner JH
Clin Immunol; 2018 Aug; 193():24-32. PubMed ID: 29842945
[TBL] [Abstract][Full Text] [Related]
7. Gut Antibody Deficiency in a Mouse Model of CVID Results in Spontaneous Development of a Gluten-Sensitive Enteropathy.
Mohammed AD; Khan MAW; Chatzistamou I; Chamseddine D; Williams-Kang K; Perry M; Enos R; Murphy A; Gomez G; Aladhami A; Oskeritzian CA; Jolly A; Chang Y; He S; Pan Z; Kubinak JL
Front Immunol; 2019; 10():2484. PubMed ID: 31708923
[TBL] [Abstract][Full Text] [Related]
8. Vedolizumab for the Treatment of Noninflammatory Bowel Disease Related Enteropathy.
Akhtar HJ; Nguyen TM; Ma C; Jairath V
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e614-e623. PubMed ID: 33618025
[TBL] [Abstract][Full Text] [Related]
9. Primary hypoparathyroidism in a patient with common variable immunodeficiency associated enteropathy.
Ismayilov R; Simsir IY; Akyol D; Ardeniz FO
Rom J Intern Med; 2021 Mar; 59(1):83-87. PubMed ID: 33098635
[No Abstract] [Full Text] [Related]
10. The role of chronic norovirus infection in the enteropathy associated with common variable immunodeficiency.
Woodward JM; Gkrania-Klotsas E; Cordero-Ng AY; Aravinthan A; Bandoh BN; Liu H; Davies S; Zhang H; Stevenson P; Curran MD; Kumararatne D
Am J Gastroenterol; 2015 Feb; 110(2):320-7. PubMed ID: 25623655
[TBL] [Abstract][Full Text] [Related]
11. Characterization of infectious and non-infectious gastrointestinal disease in common variable immunodeficiency: analysis of 114 patient cohort.
Sanchez DA; Rotella K; Toribio C; Hernandez M; Cunningham-Rundles C
Front Immunol; 2023; 14():1209570. PubMed ID: 37711607
[TBL] [Abstract][Full Text] [Related]
12. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.
Bergqvist V; Hertervig E; Gedeon P; Kopljar M; Griph H; Kinhult S; Carneiro A; Marsal J
Cancer Immunol Immunother; 2017 May; 66(5):581-592. PubMed ID: 28204866
[TBL] [Abstract][Full Text] [Related]
13. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
Zeissig S; Rosati E; Dowds CM; Aden K; Bethge J; Schulte B; Pan WH; Mishra N; Zuhayra M; Marx M; Paulsen M; Strigli A; Conrad C; Schuldt D; Sinha A; Ebsen H; Kornell SC; Nikolaus S; Arlt A; Kabelitz D; Ellrichmann M; Lützen U; Rosenstiel PC; Franke A; Schreiber S
Gut; 2019 Jan; 68(1):25-39. PubMed ID: 29730603
[TBL] [Abstract][Full Text] [Related]
14. Malignancy in common variable immunodeficiency: a systematic review and meta-analysis.
Kiaee F; Azizi G; Rafiemanesh H; Zainaldain H; Sadaat Rizvi F; Alizadeh M; Jamee M; Mohammadi S; Habibi S; Sharifi L; Jadidi-Niaragh F; Haghi S; Yazdani R; Abolhassani H; Aghamohammadi A
Expert Rev Clin Immunol; 2019 Oct; 15(10):1105-1113. PubMed ID: 31452405
[No Abstract] [Full Text] [Related]
15. Vedolizumab in Refractory Microscopic Colitis: An International Case Series.
Rivière P; Münch A; Michetti P; Chande N; de Hertogh G; Schoeters P; Ferrante M; Vermeire S; Van Assche G
J Crohns Colitis; 2019 Mar; 13(3):337-340. PubMed ID: 30329034
[TBL] [Abstract][Full Text] [Related]
16. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.
Amiot A; Grimaud JC; Peyrin-Biroulet L; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Moreau J; Gagniere C; Vuitton L; Viennot S; Aubourg A; Pelletier AL; Bouguen G; Abitbol V; Bouhnik Y; ;
Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1593-1601.e2. PubMed ID: 26917043
[TBL] [Abstract][Full Text] [Related]
18. Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data.
Card T; Ungaro R; Bhayat F; Blake A; Hantsbarger G; Travis S
Aliment Pharmacol Ther; 2020 Jan; 51(1):149-157. PubMed ID: 31747086
[TBL] [Abstract][Full Text] [Related]
19. Chronic enteropathy-related malabsorption syndrome in an adult with common variable immunodeficiency and symptomatic norovirus infection of the gut.
Jain P; Mishra A; Gupta D; Kulkarni S
BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 34016632
[TBL] [Abstract][Full Text] [Related]
20. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
Boden EK; Shows DM; Chiorean MV; Lord JD
Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
